-
Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal
•
US-based clinical-stage biopharmaceutical company, Poseida Therapeutics (NASDAQ: PSTX), which specializes in donor-derived CAR-T cell therapies, has announced a definitive merger agreement with Roche (SWX: ROG). The deal, valued at a total equity value of USD 1.5 billion, is anticipated to close in the first quarter of 2025. Expanding Allogeneic Cell…
-
Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy
•
US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant strategic investment of $50 million by Japan-headquartered Astellas (TYO: 4503). The investment consists of the purchase of 8,333,333 shares of common stock at $3.00 per share, totaling $25 million, and an additional one-time payment of…
